| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2011 | EP2311847A1 Composition containing stable vitamin B6 derivative |
| 04/20/2011 | EP2311844A1 Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof |
| 04/20/2011 | EP2311842A2 PI3K/M TOR inhibitors |
| 04/20/2011 | EP2311840A1 Spirocyclic derivatives as histone deacetylase inhibitors |
| 04/20/2011 | EP2311839A1 Oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone |
| 04/20/2011 | EP2311836A1 Process for preparing naphthyridine derivatives. |
| 04/20/2011 | EP2311835A1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/20/2011 | EP2311834A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 04/20/2011 | EP2311833A1 Tetomilast polymorphs |
| 04/20/2011 | EP2311832A1 Tetomilast polymorphs |
| 04/20/2011 | EP2311831A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| 04/20/2011 | EP2311830A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 04/20/2011 | EP2311829A1 Substituted alkylamine derivatives and methods of use |
| 04/20/2011 | EP2311828A1 Benzothiophene alkanol piperazine derivatives and their use as antidepressant |
| 04/20/2011 | EP2311825A1 Pyrimidineamines as angiogenesis modulators |
| 04/20/2011 | EP2311824A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics |
| 04/20/2011 | EP2311823A1 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
| 04/20/2011 | EP2311822A1 Gpr119 agonist |
| 04/20/2011 | EP2311821A1 Polymorphic form of Imatinib mesylate and processes for its preparation |
| 04/20/2011 | EP2311818A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| 04/20/2011 | EP2311814A1 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents |
| 04/20/2011 | EP2311811A1 Novel spiro compound, and pharmaceutical preparation comprising the same |
| 04/20/2011 | EP2311810A1 Amidine derivative |
| 04/20/2011 | EP2311809A1 Quinolinyloxyphenylsulfonamides |
| 04/20/2011 | EP2311808A1 Substituted alkylamine derivatives and methods of use |
| 04/20/2011 | EP2311807A1 Compounds and composition as protein kinase inhibitors |
| 04/20/2011 | EP2311806A2 Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists |
| 04/20/2011 | EP2311805A1 New polymorphic form of bazedoxifene acetate |
| 04/20/2011 | EP2311803A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| 04/20/2011 | EP2311802A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| 04/20/2011 | EP2311801A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2011 | EP2311799A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311798A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311797A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311796A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311795A2 Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators |
| 04/20/2011 | EP2311793A1 Crystalline levosalbutamol sulphate (Form II) |
| 04/20/2011 | EP2311500A1 Labeling targeting agents with gallium-68 and gallium-67 |
| 04/20/2011 | EP2311498A1 External preparation comprising fatty acid salt or benzoic acid salt of basic pharmacologically active component, and method for production thereof |
| 04/20/2011 | EP2311497A1 Use of oligouronates |
| 04/20/2011 | EP2311496A1 A combination of morphine and oxycodone for use in the alleviation or prevention of pain |
| 04/20/2011 | EP2311495A1 Vascularization inhibitors |
| 04/20/2011 | EP2311475A2 Extraction of pharmaceutically active cannabinoids from plant materials |
| 04/20/2011 | EP2311472A1 Cognitive disorder-ameliorating agent |
| 04/20/2011 | EP2311468A1 Gene overexpressed in cancer |
| 04/20/2011 | EP2311466A2 Antimicrobial compounds and methods for their use |
| 04/20/2011 | EP2311465A1 Remedies for diseases to be applied to eye |
| 04/20/2011 | EP2311464A1 Agents for preventing and treating disorders involving modulation of the ryr receptors |
| 04/20/2011 | EP2311463A1 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 04/20/2011 | EP2311462A1 Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| 04/20/2011 | EP2311461A1 Methods for treating cancer by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines |
| 04/20/2011 | EP2311460A1 Oxymorphone controlled release formulations |
| 04/20/2011 | EP2311459A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 04/20/2011 | EP2311458A1 Tamper resistant dosage forms |
| 04/20/2011 | EP2311457A1 Pharmaceutical compositions for treating infections with drug resistant mycobacteria |
| 04/20/2011 | EP2311456A1 Wound and mucous membrane antiseptic based on bispyridiniumalkanes |
| 04/20/2011 | EP2311455A1 Compounds for nonsense suppression, and methods for their use |
| 04/20/2011 | EP2311454A2 Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same |
| 04/20/2011 | EP2311453A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| 04/20/2011 | EP2311452A1 Topical composition comprising n-acetyl glucosamine |
| 04/20/2011 | EP2311451A1 Amino-methyl substituted tetracycline compounds |
| 04/20/2011 | EP2311450A1 Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of a Neurodegenerative Disease |
| 04/20/2011 | EP2311449A1 Orally administrated food supplement comprising carnitine |
| 04/20/2011 | EP2311448A1 Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite |
| 04/20/2011 | EP2311447A1 Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof |
| 04/20/2011 | EP2311446A1 Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| 04/20/2011 | EP2311445A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 04/20/2011 | EP2311444A1 Method for preparing a stabilised menthol emulsion |
| 04/20/2011 | EP2311443A1 Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| 04/20/2011 | EP2311442A1 Multiparticulate modified release composition |
| 04/20/2011 | EP2311441A1 Dosage formulations for acetylcholinesterase inhibitors |
| 04/20/2011 | EP2311440A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 04/20/2011 | EP2311439A1 Galenical formulations of aliskiren and hydrochlorothiazide |
| 04/20/2011 | EP2311438A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/20/2011 | EP2311435A1 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer |
| 04/20/2011 | EP2311431A1 Short duration depot formulations |
| 04/20/2011 | EP2311430A1 A plastic container comprising cyclic polyolefin layer |
| 04/20/2011 | EP2310973A2 Method for screening of 5ht7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter |
| 04/20/2011 | EP2310853A1 Assay |
| 04/20/2011 | EP2310507A1 Methods and compositions for modulating angiogenesis |
| 04/20/2011 | EP2310506A1 Rna antagonists targeting gli2 |
| 04/20/2011 | EP2310504A1 Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
| 04/20/2011 | EP2310421A1 Process for producing glycosaminoglycans |
| 04/20/2011 | EP2310401A1 Universal methylation profiling methods |
| 04/20/2011 | EP2310396A1 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
| 04/20/2011 | EP2310395A1 9-substituted-b-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| 04/20/2011 | EP2310394A1 Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists |
| 04/20/2011 | EP2310393A2 Artemisinin and derivatives thereof as antivirals |
| 04/20/2011 | EP2310392A2 Tricyclic antagonists of prostaglandin d2 receptors |
| 04/20/2011 | EP2310391A1 Pyrazine substituted purines |
| 04/20/2011 | EP2310390A1 6-(c2-6alkylseleno)purines and methods for treating neural measles viral infection therewith |
| 04/20/2011 | EP2310389A1 Heterocycles as protein kinase inhibitors |
| 04/20/2011 | EP2310388A2 Pyridopyrimidine compounds as anti-tubercular agents |
| 04/20/2011 | EP2310387A2 A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms |
| 04/20/2011 | EP2310386A1 Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity |
| 04/20/2011 | EP2310385A2 Solid pharmaceutical composition |
| 04/20/2011 | EP2310383A1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same |
| 04/20/2011 | EP2310382A1 Amidophenoxyindazoles useful as inhibitors of c-met |
| 04/20/2011 | EP2310381A1 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer |
| 04/20/2011 | EP2310380A1 Schweinfurthin analogues |